Assistant Treasurer - (Webster Groves, MO)

POSITION OVERVIEW Mallinckrodt Pharmaceuticals has announced its intent to spin off its Specialty Generics business by the 2nd half of 2019. The spin-off, if completed, will result in the independent company assuming the Mallinckrodt name, and it will be traded on the New York Stock Exchange, with its headquarters in the St. Louis, Mo., area. The name Mallinckrodt and its historical values of quality, integrity and service have long been associated with the Specialty Generics business St. Louis heritage. With approx 1,600 employees globally, the newly spun company will include an acetaminophen business, a portfolio of both active pharmaceutical ingredients and generic finished dose forms of controlled substances and other drugs, a niche specialty generics development portfolio, a portfolio of 3rd-party promoted and non-promoted branded drugs, and a strong U.S. manufacturing footprint. SUMMARY